DAVID W GRYSKA
CIK 1202335 · Executive Vice President, CFO · last filed 2026-06-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.72M
Companies
10
Total Filings
116
Lifetime Open-Market Net
-$23.62M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FBRX | Director | 148,514 | $17.56 | $2.61M | $0 | 6 | 2026-06-02 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Director | 19,851 | $15.00 | $297.8K | $38.9K | 5 | 2025-06-16 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | -$9.71M | 42 | 2023-12-15 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Director | 0 | $15.25 | $0 | $0 | 7 | 2022-11-21 |
| GW PHARMACEUTICALS PLC (GWPH) Delisted | Director | — | $218.96 | — | $0 | 2 | 2021-02-24 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 1,387 | — | — | -$925.8K | 14 | 2020-12-31 |
| INCY | Executive Vice President, CFO | 10,235 | $108.53 | $1.11M | -$9.18M | 17 | 2018-07-18 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | — | — | — | $0 | 1 | 2013-05-01 |
| CELGENE CORP /DE/ (CELG) Delisted | Chief Financial Officer | 3,763 | — | — | -$3.84M | 20 | 2010-07-15 |
| COTHERIX INC (CTRX) Delisted | Director | — | — | — | $0 | 1 | 2007-01-10 |
Recent Filings · Page 8 of 12
116 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-05-29 | PDL BIOPHARMA, INC. (PDLI) Delisted | Grant (A) | +22,059 | $150.0K | EDGAR |
| 2015-05-19 | Seagen Inc. (SGEN) Delisted | Grant (A) | +3,700 | $0 | EDGAR |
| 2015-04-14 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Grant (A) | +1,700 | $0 | EDGAR |
| 2015-04-10 | Seagen Inc. (SGEN) Delisted | Exer (M) | +5,000 | $41.9K | EDGAR |
| 2015-01-09 | INCY | Grant (A) | +3,022 | $0 | EDGAR |
| 2014-11-04 | INCY | Grant (A) | +7,828 | $0 | EDGAR |
| 2014-03-10 | PDL BIOPHARMA, INC. (PDLI) Delisted | Grant (A) | +5,981 | $50.0K | EDGAR |
| 2013-09-05 | Seagen Inc. (SGEN) Delisted | Mixed | — | -$324.0K | EDGAR |
| 2013-05-21 | Seagen Inc. (SGEN) Delisted | Grant (A) | +3,500 | $0 | EDGAR |
| 2013-05-01 | HYPERION THERAPEUTICS INC (HPTX) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.